A theoretical analysis of HLA-DRβ1*0301-CLIP complex using the first three multipolar moments of the electrostatic field

Biochimie

Volumn 88, Issue 9, 2006, Pages 1307-1311

  Balbín, Alejandro ^a   Cárdenas, Constanza ^a,b   Villaveces, José Luis ^b   Patarroyo, Manuel E ^a,b  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Electrostatic potential; MHC pockets; Multipolar moments; Theoretical study of MHC

Indexed keywords

HLA DR ANTIGEN; B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2; HLA-DRB1 ANTIGEN; MULTIPROTEIN COMPLEX;

ARTICLE; CALCULATION; ELECTRICITY; HLA SYSTEM; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; THEORETICAL MODEL; ALGORITHM; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; INVARIANT CHAIN; METABOLISM; QUANTUM THEORY;

ALGORITHMS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; COMPUTER SIMULATION; ELECTROSTATICS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; QUANTUM THEORY;

EID: 33748808676     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2006.05.009     Document Type: Article

References (20)

1. Ban Y., Davies T., Greenberg D., Conception E., Osman R., Oashi T., and Tomer Y. Arginine at position 74 of the HLA-DR β1 chain is associated with Graves' disease. Genes Immun. 5 (2004) 203-208
2. Schur P. Genetics of systemic lupus erythematosus. Lupus 4 (1995) 425-437
3. Ghosh P., Amaya M., Mellins E., and Wiley D. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378 (1995) 457-462
4. Liang M., Lee C., Xia Y., and McConnell H. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC. Biochemistry 35 (1996) 14374-14742
5. Doebele R., Paschine A., Liu W., Zaller D., Belmares M., Busch R., and Mellins E. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism. J. Immunol. 170 (2003) 4683-4692
6. Gautam A., Yang M., Milburn P., Baker R., Bhatnagar A., McCluskey J., and Boston T. Identification of residues in the class II-associated li peptide (CLIP) region of invariant chain that affect efficiency of MHC class II mediated antigen presentation in an allele-dependent manner. J. Immunol. 159 (1997) 2782-2788
7. Lee C., and McConnell H. A general model of invariant chain association with class II major histocompatibility complex proteins. Proc. Natl. Acad. Sci. USA 92 (1995) 8269-8273
8. Cárdenas C., Villaveces J.L., Bohorquez H., Llanos E., Suárez C., Obregón M., and Patarroyo M.E. Quantum chemical analysis explains hemagglutinin peptide-MHC class II molecule HLA-DRβ1*0101 interactions. Biochemical and Biophysical Reasearch Communications 323 (2004) 1265-1277
9. Cárdenas C., Villaveces J.L., Suárez C., Obregón M., Ortíz M., and Patarroyo M.E. A comparative study of MHC class-II HLA-DR β1*0401-Col II and HLA-DR β1*0401-HA complexes: a theoretical point of view. J. Struct. Biol. 149 (2005) 38-52
10. Cárdenas C., Ortíz M., Balbín A., Villaveces J.L., and Patarroyo M.E. Allele effect on MHC-peptide interaction: a theoretical analysis of HLA-DR β1*0101-HA and HLA-DR β1*0401-HA complexes. Biochem. Biophys. Res. Commun. 330 (2005) 1162-1167
11. Stern L., Brown J., Jardetzky T., Gorga J., Urban R., Strominger J., and Wiley D. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368 (1994) 215-221
12. Frisch M., Trucks G., Schlegel H., Scuseria G., Robb M., Cheeseman J., Montgomery V.Z.J., Stratmann R., Burant J., Dapprich S., Millam J., Daniels A., Kudin A., Strain M., Farkas O., Tornasi J., Barone V., Cossi M., Cammi R., Mennucci B., Pomelli C., Adamo C., Clifford S., Ochterski J., Petterson G., Ayala P., Cui Q., Malick K.M.D., Rabuck A., Raghavachari K., et al. Gaussian'98, revision A.5 (1998), Gaussian Inc, Pittsburg PA
13. Schafroth H., and Floudas C. Predicting peptide binding to MHC pockets via molecular modeling, implicit solvation, and global optimization. Proteins 54 (2004) 534-556
14. The HLA Facts Book (2000), Academic Press, London
15. Chelvanayagam G. A road map for HLA-DR peptide binding specificities. Hum. Immunol. 58 (1997) 61-69
16. Humphrey W., Dalke A., and Schulten K. VMD-Visual Molecular Dynamics. J. Mol. Graph. 14 (1996) 33-38
17. Dewar M., Zoebisch E., and Healy E. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107 (1985) 3902-3909
18. Biopolymer Group Software. Insight II (2000), Accelrys Software, USA
19. Demotz S., Barbey C., Corradin G., Amoroso A., and Lanzavecchia A. The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur. J. Immunol. 23 (1993) 425-432
20. Krieger J., Karr R., Grey H., Yu W., O'Sullivan D., Batovsky L., Zheng Z., Colon S., Gaeta F., and Sidney J. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J. Immunol. 146 (1995) 2331-2340